Description: Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets. The company develops AVA6000, a peptide drug conjugate form of doxorubicin that is in Phase I clinical trial to treat locally advanced or metastatic solid tumour; AVA3996, a tumor-activated proteasome inhibitor based on Velcade; and AVA032, a bispecific molecule which is in pre-clinical trials that regulates the activation and proliferation of immune cells. It develops AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing Affimer based therapeutics. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Home Page: www.avacta.com
Thorp Arch Estate
Wetherby,
LS23 7FA
United Kingdom
Phone:
44 1904 217 070
Officers
| Name | Title |
|---|---|
| Dr. Christina Marie Coughlin B.S., M.D., Ph.D. | CEO, Interim Chief Medical Officer and Director |
| Mr. Tony Gardiner | CFO & Company Secretary |
| Dr. Michelle Morrow Ph.D. | Chief Scientific Officer |
| Ms. Emma Wright | Group In-House Counsel |
| Mr. Michael Vinegrad | Group Communications Director |
| Mr. R. Craig Slater FCA | Chief Operating Officer of Diagnostics |
| Mr. David Wilson | Chief Commercial Officer of Diagnostics |
| Ms. Karen Harrison | Chief Operating Officer of Therapeutics Division |
| Ms. Anne McGurk | Joint Managing Director of Launch Diagnostics |
| Mr. Ian Jones | Joint Managing Director of Launch Diagnostics |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.0307 |
| Price-to-Sales TTM: | 9.1036 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 154 |